Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Completed
Trial end date:
2011-05-12
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the pharmacokinetic (PK) and
pharmacodynamic (PD) parameter estimates of eculizumab to confirm the dose regimens for
pediatric and adolescent participants with PNH.